Scentia Pharmaceuticals

Scientia Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company leverages its expertise in structure-based drug design to target key drivers of cancer, such as FGFR, EGFR, and ALK. Its lead candidate, SC-0062, is a potent and selective pan-FGFR inhibitor currently being evaluated in Phase 1/2 clinical trials for patients with advanced solid tumors harboring FGFR alterations. Scientia operates with a dual presence in Shanghai, China, and Exton, Pennsylvania, aiming to address significant unmet medical needs in global markets.